Financial Data and Key Metrics Changes - The third quarter revenue was $697,000, which included first-time staking rewards income of $342,000, marking a significant increase from the prior year period [25] - Cost of revenue decreased to $103,000 from $187,000 in the prior year, primarily due to reduced inventory reserve and production scrap expenses [25] - Total operating expenses for the third quarter were $36 million, compared to $3.9 million in the third quarter of 2024, resulting in a loss from operations of $35.4 million, up from a loss of $4.1 million in the prior year [26] - The net loss for the third quarter was $352.8 million, or a loss of $32.89 per share, compared to a net loss of $3.7 million in the prior year [27][28] Business Line Data and Key Metrics Changes - The company has increased its holdings of SOL by approximately $100,000 in the first month of operation, totaling over 2.3 million tokens [15] - The average gross staking yield for October was 7.03% APY, outperforming the stake-weighted average of the top 10 largest validators [16] Market Data and Key Metrics Changes - Trading volume in HSDC has significantly outperformed the average of peer DATs, indicating growing awareness of Solana's fundamentals [10] - The company has been actively engaging with the Asian market, which is seen as a significant under-penetrated area with high potential for Solana [9] Company Strategy and Development Direction - The company aims to build the "Berkshire Hathaway of the Solana ecosystem," focusing on compounding shareholder value and maintaining a strong balance sheet [11] - The digital asset treasury strategy is centered around three pillars: advocacy, capital markets, and treasury management [5][6] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that the digital asset treasury market has cooled after a period of rapid expansion, entering an execution and consolidation phase [14] - The company believes it has the necessary ingredients for long-term success, including balance sheet strength and institutional sponsorship [15] Other Important Information - The company successfully raised over $500 million to fund its digital asset treasury strategy in September [4] - The PoNS device submission for FDA 510(k) designation has been filed, reflecting positive clinical outcomes from the stroke registration program [22][23] Q&A Session Summary - No questions were raised during the Q&A session, and the call concluded with closing remarks from management [29][30]

Financial Data and Key Metrics Changes - The third quarter revenue was $697,000, which included first-time staking rewards income of $342,000, marking a significant increase from the prior year period [25] - Cost of revenue decreased to $103,000 from $187,000 in the prior year, primarily due to reduced inventory reserve and production scrap expenses [25] - Total operating expenses for Q3 2025 were $36 million, compared to $3.9 million in Q3 2024, resulting in a loss from operations of $35.4 million, up from a loss of $4.1 million in the prior year [26] - The net loss for Q3 2025 was $352.8 million, or a loss of $32.89 per share, compared to a net loss of $3.7 million in the prior year [27][28] Business Line Data and Key Metrics Changes - The company has increased its holdings of SOL by approximately 100,000 tokens in the first month of operation, totaling over 2.3 million tokens [15] - The average gross staking yield for October was 7.03% APY, outperforming the stake-weighted average of the top 10 largest validators [16] Market Data and Key Metrics Changes - Trading volume in HSDC has significantly outperformed the average of peer DATs, indicating growing awareness of Solana's fundamentals [10] - The company has been actively engaging with institutional investors and has appeared in major media outlets, enhancing its visibility in the market [8] Company Strategy and Development Direction - The company aims to build the "Berkshire Hathaway of the Solana ecosystem," focusing on maximizing shareholder value through disciplined execution of its digital asset treasury strategy [11] - The strategic focus includes advocacy for Solana, capital markets management, and treasury management, with an emphasis on operational excellence and capital discipline [14][15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a cooling digital asset treasury market but expressed confidence in the company's ability to navigate the execution and consolidation phase [12][14] - The company believes it has the necessary ingredients for long-term success, including balance sheet strength and institutional sponsorship [15] Other Important Information - The company successfully raised over $500 million to fund its digital asset treasury strategy in September 2025 [4] - The PONS device has shown positive clinical outcomes, supporting its submission for FDA 510(k) designation [22] Q&A Session Summary - No questions were raised during the Q&A session, indicating a lack of immediate inquiries from investors [30]

[Music] [Applause] You will never get better. You will never be without pain. You better have to learn to live with it.Has anyone here or anyone you know well ever heard words like these. Because these are words people who are diagnosed with chronic pain hear often. And these words hurt. They these words sounds heavy.These words almost reduce their identity to one thing. You are pain. But today I want to convince you to never say never even in the context of chronic pain.Let's start with language. The word ...

Financial Data and Key Metrics Changes - For Q3 2025, the company reported a loss from operations of $4 million, compared to a loss of $3 million in Q3 2024, primarily due to increased R&D expenses of $800,000 and additional administrative expenses of $400,000 [30][31] - The company reported revenue for the first time in its history, approximately $240,000, reflecting only 22 days of revenue from a single clinic [31][32] - As of September 30, 2025, the company had approximately $7.1 million in cash and cash equivalents, with total cash potentially reaching $10.3 million [31] Business Line Data and Key Metrics Changes - The company has advanced its drug approval applications for Ketaphree, NRx 100, and NRx 101, and has expanded its NRx 101 pipeline [3][4] - The acquisition of Durra Medical has initiated revenue generation, with plans to grow from two clinics to six or more by year-end [12][32] - The company anticipates significant revenue growth from short-term multimodality treatments that are already reimbursed at higher levels [13] Market Data and Key Metrics Changes - The market for ketamine is projected at approximately $750 million, with the company aiming to provide a preservative-free formulation [23] - The estimated market for NRx 101, targeting suicidal bipolar depression, is in excess of $1 billion [28] Company Strategy and Development Direction - The company aims to transform the treatment of severe depression and PTSD through innovative therapies combining D-cycloserine and TMS [4][11] - The strategy includes expanding the network of interventional psychiatry clinics and enhancing shareholder value through drug development and clinic acquisitions [30][33] - The company is focused on addressing the national crisis of suicide and improving treatment options for mental health disorders [30] Management's Comments on Operating Environment and Future Outlook - Management views the recent quarter as a watershed moment in the treatment of severe depression and PTSD, with promising data supporting their therapies [4][11] - The company is optimistic about the FDA's receptiveness to accelerated approval applications for NRx 100 and NRx 101, especially given the significant unmet medical need [25][40] - The leadership team is actively engaging with military and veterans' affairs leaders to address suicide prevention [20][30] Other Important Information - The company holds rights to over 70 patents related to the use of D-cycloserine in treating depression and PTSD [7] - The FDA has granted breakthrough therapy designation for NRx 101, and the company is pursuing both NDA and ANDA pathways for its products [18][24] Q&A Session Summary Question: Can you clarify the unique benefits of DCS compared to ketamine in treatment? - Management explained that DCS acts as a mixed agonist-antagonist and enhances neuroplasticity, which may improve TMS effectiveness [34][35] Question: What is the procedure for using DCS in conjunction with TMS? - The company has an expanded access protocol for DCS, allowing physicians to access it for treatment while collecting data on outcomes [38] Question: What feedback has been received regarding the accelerated approval strategy for NRx 100? - Management indicated that they expect to hear about the CMPV this year and are preparing to submit real-world data to support their NDA filing [39][40] Question: How will the company ensure adequate supply if the FDA bans preservative-containing formulations? - The company has a manufacturing capacity that could meet the entire U.S. demand for ketamine, utilizing a blow-fill seal presentation for production [41] Question: What is the commercialization strategy for NRx 100 and NRx 101? - NRx 100 will likely require a medical science liaison approach, while NRx 101 may necessitate a sales force due to its specific target market [44][45]

Financial Data and Key Metrics Changes - For Q3 2025, the company reported a loss from operations of $4 million, compared to a loss of $3 million in Q3 2024, primarily due to increased R&D expenses of $800,000 and additional administrative expenses of $400,000 [30][31] - The company reported revenue for the first time in its history, approximately $240,000, reflecting only 22 days of revenue from a single clinic [31][32] - As of September 30, 2025, the company had approximately $7.1 million in cash and cash equivalents, which would have been $10.3 million if not for a subscription receivable [31][32] Business Line Data and Key Metrics Changes - The company has advanced its drug approval applications for Ketaphree, NRx 100, and NRx 101, and has expanded its NRx 101 pipeline [3][4] - The acquisition of Durra Medical has initiated revenue generation, with plans to grow from two clinics to six or more by year-end [12][32] - The company anticipates significant revenue growth from short-term multimodality treatments that are already reimbursed at higher levels [13] Market Data and Key Metrics Changes - The market for ketamine is projected at approximately $750 million, with the company aiming to provide a preservative-free option [23] - The estimated market for NRx 101, targeting suicidal bipolar depression, is in excess of $1 billion [28] Company Strategy and Development Direction - The company aims to transform the treatment of severe depression and PTSD through innovative therapies combining D-cycloserine and TMS [4][11] - The strategy includes expanding the network of interventional psychiatry clinics and engaging with the payer community to adapt to changing treatment paradigms [12][15] - The company is focused on advancing drug development initiatives and planned clinic acquisitions to build long-term shareholder value [33] Management's Comments on Operating Environment and Future Outlook - Management views the recent quarter as a watershed moment in the treatment of severe depression and PTSD, with promising data supporting their therapies [4][11] - The leadership team is optimistic about the potential for accelerated drug approvals and the impact on addressing the national crisis of suicide [30][46] - The company believes it is better positioned than ever to build shareholder value and address mental health challenges [30] Other Important Information - The company holds rights to over 70 patents related to the use of D-cycloserine in treating depression and PTSD [7] - The FDA has granted breakthrough therapy designation for NRx 101, and the company is pursuing two approval pathways for its ketamine product [18][24] Q&A Session Summary Question: Can you clarify the DCS results with TMS and its unique position? - The company explained that DCS is a mixed agonist-antagonist and has shown to enhance neuroplasticity, which is critical for its effectiveness in combination with TMS [34][35] Question: What feedback have you received on the accelerated approval strategy for NRx 100? - The company indicated that they expect to hear about the CMPV this year and are preparing to file for accelerated approval with substantial real-world data [39][40] Question: How will you position Hope to become an early adopter of the 1D protocol? - The company has partnered with AMPA and is the first site in Florida to implement the 1D protocol, which is readily deployable [42][43] Question: What is your commercialization strategy for NRx 100 and 101? - The company plans to utilize medical science liaison functions for NRx 100 and anticipates building a sales force for NRx 101, with potential partnerships with larger commercial entities [44][45]

Financial Data and Key Metrics Changes - For Q3 2025, the company reported a loss from operations of $4 million, compared to a loss of $3 million in Q3 2024, primarily due to increased R&D expenses of $800,000 and additional administrative expenses of $400,000 [28][29] - The company generated revenue for the first time, approximately $240,000, reflecting only 22 days of operations from a single clinic [29][30] - As of September 30, 2025, the company had approximately $7.1 million in cash and cash equivalents, with total cash potentially reaching $10.3 million [29] Business Line Data and Key Metrics Changes - The company has advanced its drug approval applications for Ketaphree, NRx 100, and NRx 101, and has expanded its NRx 101 pipeline [3][4] - Hope Therapeutics, a subsidiary, initiated revenue generation with the acquisition of Durra Medical, and plans to expand from two clinics to six or more by year-end [12][26] Market Data and Key Metrics Changes - The market for ketamine is projected at approximately $750 million, with the potential for significant growth through the introduction of preservative-free formulations [21][22] - The estimated market for NRx 101, targeting suicidal bipolar depression, exceeds $1 billion [26] Company Strategy and Development Direction - The company aims to transform the treatment of severe depression and PTSD through innovative therapies combining D-cycloserine and TMS [4][10] - The strategy includes expanding clinic operations and integrating new treatment protocols to enhance patient outcomes and revenue growth [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, anticipating significant revenue growth as more clinics are integrated and additional acquisitions are pursued [12][30] - The leadership highlighted the importance of addressing the national crisis of suicide and the potential for their therapies to meet unmet medical needs [28][30] Other Important Information - The company holds rights to over 70 patents related to the use of D-cycloserine in treating various brain disorders [6] - The FDA has granted breakthrough therapy designation for NRx 101, and the company is pursuing accelerated approval pathways for its drug applications [22][36] Q&A Session Summary Question: Can you clarify the unique benefits of DCS compared to ketamine in treatment? - Management explained that DCS acts as a mixed agonist-antagonist and enhances neuroplasticity, which may improve the effectiveness of TMS [32][34] Question: What is the anticipated timeline for FDA feedback on accelerated approval? - The company expects to hear about the Commissioner's National Priority Voucher (CMPV) this year, which could impact the PDUFA timeline [36][37] Question: How will the company ensure adequate supply if the FDA bans preservative-containing formulations? - The company has a manufacturing process that allows for high production capacity, potentially supplying all required ketamine in the U.S. [38] Question: What is the commercialization strategy for NRx 100 and NRx 101? - NRx 100 will likely require a medical science liaison approach, while NRx 101 may necessitate a sales force due to its specific target market [40][41]

Neuroplasticity & Child Development - Neuroplasticity is the brain's ability to reorganize itself in response to new information [3] - Children's brains have a high number of synapses, peaking around age 2-3 with one quadrillion (1,000,000,000,000,000) synapses, making them highly sensitive to new information [3][4] - Early language learning exemplifies neuroplasticity, enabling native-like accents and complex grammar understanding [7] - Early years significantly impact a child's development, influencing their future [8] Examples of Neuroplasticity - Chess prodigies demonstrate neuroplasticity by quickly identifying patterns and memorizing sequences [5][6] - Children can outperform adults in certain skills due to their neuroplastic brains [2][6] Implications for Education - Providing the right environment is crucial for young people to achieve their full potential [9]

[Applause] What if I told you your brain was like play-doh. It's soft, malleable, and everchanging. Each one of your thoughts leaves an imprint just like this.The more you repeat this thought, the deeper the imprint becomes. This is how your brain forms neural pathways. We all have good and bad days and our brain takes note of them all.Good and bad thoughts leave a mark. But the good news are these marks are reversible. You are never stuck.You can always reshape your brain. And the term for this is neuropla ...

Core Viewpoint - Solana Company has applied to cease being a reporting issuer in multiple Canadian jurisdictions, which will relieve it from filing financial statements and continuous disclosure documents in Canada while continuing to comply with U.S. securities laws [1][2]. Company Overview - Solana Company (NASDAQ: HSDT) is a leading neurotech firm focused on addressing neurologic deficits through an orally applied technology platform that enhances the brain's physiological compensatory mechanisms and promotes neuroplasticity [5]. - The company also operates a digital asset treasury (DAT) aimed at acquiring and holding Solana (SOL), with the goal of maximizing SOL per share through strategic capital market use and on-chain opportunities [5]. Regulatory Actions - The company has requested an order from the British Columbia and Ontario Securities Commissions to stop being a reporting issuer in Canada, which would eliminate the requirement for financial disclosures in those jurisdictions [1][2]. - If granted, the company will continue to file necessary financial statements under U.S. securities law and Nasdaq rules [2].

music. It's a gift of therapy to the body and beauty to the soul. [Music] That was a short segment of a lovely piece by Johan Sebastian Bach.Here's another song you're probably familiar with. [Music] That was Twinkle, Twinkle, Little Star. These two pieces I just played have very different formats.One is woven into a beautiful harmonic tapestry and the other is a simple melodic line. But when learning either of these pieces, it all starts with figuring out how to play just one note at a time. I became fasci ...